Molecular Formula | C25H27ClN6O3
|
Molar Mass | 494.97 |
Density | 1.314 |
Solubility | Soluble in DMSO (13 mg/ml) at 25 °C, water (<1 mg/ml) at 25 °C, and ethanol (<1 mg/ |
Appearance | White to beige powder |
pKa | 12.78±0.70(Predicted) |
Storage Condition | -20℃ |
MDL | MFCD16621244 |
Use | An EGFR phosphorylation inhibitor |
In vitro study | WZ4002 also inhibits other EGFR genotypes, such as IC50 of 2 and 6 nM for E746_A750 and E746_A750/T790M, respectively. When WZ4002 acts on the wild type EGFR, the IC50 is 32 nM. WZ4002 inhibits the phosphorylation of EGFR, AKT and ERK1/2 in non-small cell lung cancer (NSCLC) cells. WZ4002 inhibits EGFR phosphorylation when acting on NIH-3T3 cells expressing different EGFRT790M mutant alleles. The dissociation constant of the kinase was determined, and the experimental group under the action of WZ4002 was 95% higher than the control group under the action of DMSO. WZ4002 has a higher effect on EGFR than WZ3146 due to obtaining an n-methoxy group when C2 aniline is substituted. Compared with quinazoline inhibitors, WZ4002 is 100 times less effective in the phosphorylation of wild-type EGFR. WZ4002 was much more effective in inhibiting the kinase activity of recombinant L858R/T790M protein EGFR than wild-type EGFR, while the inhibitory effects of HKI-272 and Gefitinib were just opposite to wz4002. In addition, the phosphorylation of EGFR of Src TKI-resistant H1975 cells and HCC827 cells was completely inhibited by the third generation EGFR TKI, wz4002. |
In vivo study | A murine model containing the T790M mutation was treated for 2 weeks to study the efficacy of WZ4002, and it was found that WZ4002 treatment resulted in significant tumor regression compared to the control group. Treatment with low dose WZ4002, and high dose WZ4002, resulted in a decrease in mean uptake of 26% and 36%, respectively. |